Merus
![Merusā Zeno Improves Outcomes in NRG1+ Cancers (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Merus-Zeno-Shows-Higher-Response-Rates-in-NRG1-Pancreatic-and-Lung-Cancers-ESMO-2023.jpg)
Merusā Zeno Shows Higher Response Rates in NRG1+ Pancreatic and Lung Cancers (ESMO 2023)
Anika Sharma
ESMO 2023: 1618P Currently, Ipsen’s Onivyde is the standard of care, but it offers only a 7% chance of response ...
![Zenocutuzumab receives Breakthrough Designation from the FDA for NRG1+ Pancreatic Cancer](https://pharmtales.com/wp-content/uploads/2023/07/Zenocutuzumab-receives-Breakthrough-Designation-from-the-FDA-for-NRG1-Pancreatic-Cancer.jpg)
Zenocutuzumab receives Breakthrough Designation from the FDA for NRG1+ Pancreatic Cancer
SG Tylor
Source – Merus On July 5, The FDA has granted breakthrough therapy designation to zenocutuzumab (MCLA-128) as a treatment for ...